PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Rhenium”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed2001

Rhenium(I) carbonyl complexes of 2,4,6-tris(2-pyridyl)-1,3,5-triazine (TPT). Rhenium(I)-promoted methoxylation of the triazine ring carbon atom in dinuclear rhenium complexes.

2,4,6-Tris(2-pyridyl)-1,3,5-triazine (TPT) bridged dinuclear rhenium(I) tricarbonyl halide complexes with the composition (mu-TPT)[ReX(CO)(3)](2) (3, X = Cl; 4, X = Br) can be made either by one-pot reaction of TPT with 2 equiv of [ReX(CO)(5)] (X = Cl and Br) in chloroform or by reacting mononuclear [ReX(CO)(3)(TPT)] (2) (1, X = Cl; 2, X = Br) with an excess amount of [ReX(CO)(5)]. Crystal data are as follows. 1: monoclinic, P2(1)/c, a = 11.751(1) A, b = 11.376(1) A, c = 15.562(2) A, beta = 103.584(2) degrees, V = 2022.0(4) A(3), Z = 4. 2: monoclinic, P2(1)/c, a = 11.896(1) A, b = 11.396(1) A, c = 15.655(1) A, beta = 104.474(2) degrees, V = 2054.9(3) A(3), Z = 4. 3: triclinic, P1, a = 11.541(2) A, b = 12.119(2) A, c = 13.199(2) A, alpha = 80.377(2) degrees, beta = 76.204(3) degrees, gamma = 66.826(2) degrees, V = 1642.5(4) A(3), Z = 2. Crystals of 4 crystallized from acetone: triclinic, P1, a = 11.586(5) A, b = 12.144(5) A, c = 13.364(6) A, alpha = 80.599(7) degrees, beta = 76.271(8) degrees, gamma = 67.158(8) degrees, V = 1678.0(12) A(3), Z = 2. Crystals of 4' are obtained from CH(2)Cl(2)-pentane solution: monoclinic, C2/c, a = 17.555(4) A, b = 15.277(3) A, c = 13.093(3) A, beta = 111.179(3) degrees, V = 3274.0(12) A(3), Z = 4. By contrast, similar reactions in the presence of methanol yielded complexes with the composition [mu-C(3)N(3)(OMe)(py)(2)(pyH)][ReX(CO)(3)](2) (5, X = Cl; 6, X = Br). Crystal data for 5: monoclinic, C2/c, a = 26.952(2) A, b = 16.602(1) A, c = 14.641(1) A, beta = 116.147(1) degrees, V = 5880.5(8) A(3), Z = 8. 6: monoclinic, C2/c, a = 27.513(3) A, b = 16.740(2) A, c = 14.837(2) A, beta = 116.925(2) degrees, V = 6092.8(10) A(3), Z = 8. An unusual metal-induced methoxylation at the carbon atom of the triazine ring of the bridging TPT ligand was observed. The nucleophilic attack of MeO(-) on C(3) results in a tetrahedral geometry around the carbon atom. Concomitantly, the uncoordinated pyridyl ring is protonated and rotated into a perpendicular orientation relative to the central C(3)N(3) ring. Reaction of TPT with [NEt(4)](2)[ReBr(3)(CO)(3)] in benzene-methanol resulted in an unexpected dinuclear complex 7, with formulation [mu-C(3)N(3)(OMe)(py)(3)][Re(CO)(3)][ReBr(CO)(3)]. The methoxylated TPT ligand functions simultaneously as a tridentate and bidentate ligand with two fac-Re(CO)(3)(+) cores. Crystal data for 7: monoclinic, P2(1)/n, a = 12.114(1) A, b = 14.878(1) A, c = 15.807(1) A, beta = 104.601(1) degrees, V = 2756.9(3) A(3), Z = 4.

Journal Article↗
PubMed1994

Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies.

BACKGROUND: Antibody sulfhydryl groups can act as effective carriers of reduced technetium and rhenium species for radioimmunodetection and radioimmunotherapy. METHODS: Intact immunoglobulin G and fragments were labeled with the isotopes and examined in vitro and in vivo. RESULTS: Technetium bound to intact immunoglobulin G was found to be the most stable species in vitro, but in vivo, clearances of technetium and rhenium bound to intact antibody were similar. Serum clearances were faster than those seen for the corresponding radioiodinated antibodies. In vivo clearance rates of the radiolabeled fragments were similar, with kidney uptake and retention seen. Rhenium-labeled antibodies, despite a greater tendency toward in vitro reoxidation than technetium-labeled antibodies, did not show enhanced kidney clearance in animal models. Rhenium-188 and technetium-99m were obtained from similar generator systems in carrier-free form. Using rhenium-188 spiked with cold rhenium, it was determined that approximately one rhenium atom per molecule of antibody can be conjugated directly. Rhenium-186 also was coupled at almost a 1:1 ratio to antibody. CONCLUSIONS: Only radiolysis concerns will limit the amount of rhenium-188 conjugated to antibody. Large doses of antibody will be necessary to deliver rhenium-186 at this isotope's currently available specific activity. Otherwise, higher specific activity rhenium-186, and/or greater loading capacity of rhenium-186 onto antibody, will be needed to generate the type of product that will be usable at a clinical dose of several hundred millicuries.

Animals↗
PubMedDate not supplied

Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment.

Rhenium-188 (beta- = 2.2 MeV; gamma = 155 keV; T1/2 16.9 hours) is an attractive therapeutic radioisotope which is produced from decay of the reactor-produced tungsten-188 parent (T1/2 69 days) and thus conveniently obtained on demand by elution from the alumina-based tungsten-188 /rhenium-188 generator system. The rhenium-188 is obtained as sodium perrhenate by elution of the generator with 0.9% saline. The post elution use of disposable tandem, ion-exchange columns is a simple method for the concentration of rhenium-188 saline solutions with specific volumes > 500 mCi/ml. This method can also extend the useful shelf-life of the generator, which can be as long as one year. The long useful shelf-life of the generator is expected to provide rhenium-188 at very reasonable costs for routine preparation of a variety of radiopharmaceuticals for the treatment of a variety of cancers including breast cancer. We are evaluating two types of Re-188-labeled agents under investigation which have potential for the treatment of breast cancer. Rhenium-188-labeled hydroxyethylidenediphosphonate (HEDP) and Re-188-dimercaptosuccinic acid (DMSA) are being applied for palliative treatment of pain associated with skeletal metastases, and the Re-188-RC-160 somatostatin analogue [cyclic NH2-(D)-Phe-Cys-Try-(D)-Trp-Lys-Val-Cys-Trp-NH2] for somatostatin-receptor-positive tumors. The results of initial clinical studies with the two bone pain agents demonstrate good targeting to skeletal metastases, and use of Re-188-HEDP has resulted in pain palliation with minimal bone marrow suppression in the initial patient studies. While these initial studies have been conducted in patients with prostate cancer, similar results are expected in planned studies in breast cancer patients. In animal studies, Re-188-RC-160 has been successfully used for the local/regional treatment of experimental breast cancer and other cancers. Re-188-RC-160 binds to somatostatin-receptor-positive cells both in vitro and in vivo, including breast cancer cells (ZR-75-1 breast carcinoma and NCI-H69 human small cell ling carcinoma), but not to binding-negative cells (Raji, Burkitt's lymphoma). A structurally similar Re-188-cyclic peptide with different binding specificity (CTOP [cyclic NH2-(D)-Phe-Cys-Try-(D)-Trp-Orn-Thr-Pen-Thr-ol]; an opiate-receptor antagonist) did not bind to target cells. Both gentisic acid and ascorbic acid are present in the Re-188-HEDP and Re-188-RC-160 formulations, and have been found to also significantly reduce radiolytic degradation of the somatostatin peptide analogues, and may have general application in the stabilization of Re-188-labeled radio-pharmaceuticals.

Aluminum Oxide↗
PubMed1997

Rhenium-188 labeled hydroxyapatite and rhenium-188 sulfur colloid. In vitro comparison of two agents for radiation synovectomy.

AIM: One therapeutic approach to rheumatoid arthritis and other inflammatory arthropathies besides surgical removal of inflamed synovium is radiation synovectomy using beta-emitting radionuclides to destroy the affected synovial tissue. Up to now the major problem associated with the use of labeled particles or colloids has been considerable leakage of radionuclides from the injected joint coupled with high radiation doses to liver and other non target organs. In this study we compared 188Re labeled hydroxyapatite particles and 188Re rhenium sulfur colloid for their potential use in radiation synovectomy. METHODS: To this end we varied the labeling conditions (concentrations, pH-value, heating procedural and analyzed the labeling yield, radiochemical purity, and in vitro stability of the resulting radiopharmaceutical. RESULTS: After optimizing labeling conditions we achieved a labeling yield of more than 80% for 188Re hydroxyapatite and more than 90% for the rhenium sulfur colloid. Both of the radiopharmaceuticals can be prepared under aseptic conditions using an autoclave for heating without loss of activity. In vitro stability studies using various challenge solutions (water, normal saline, diluted synovial fluid) showed that 188Re labeled hydroxyapatite particles lost about 80% of their activity within 5 d in synovial fluid. Rhenium sulfur colloid on the other hand proved to be very stable with a remaining activity of more than 93% after 5 d in diluted synovial fluid. CONCLUSION: These in vitro results suggest that 188Re labeled rhenium sulfur colloid expects to be more suitable for therapeutic use in radiation synovectomy than the labeled hydroxyapatite particles.

Arthritis, Rheumatoid↗
PubMed1997

Preparation of Rhenium(I) and Rhenium(II) Amine Dinitrogen Complexes and the Characterization of an Elongated Dihydrogen Species.

A series of rhenium(I) dinitrogen complexes were prepared containing predominantly amine ligands. On the basis of infrared and electrochemical data, a system was selected that was anticipated to be a suitable precursor for an elongated dihydrogen complex. Upon oxidation by AgOTf, the dinitrogen ligand of fac-[Re(PPh(3))(PF(3))(dien)(N(2))](+) (3) is replaced with triflate to generate 13, fac-[Re(PPh(3))(PF(3))(dien)(OTf)]OTf, a convenient precursor to rhenium(II) and rhenium(I) amine complexes. Reduction of the rhenium(II) triflate 13 under 1 atm of hydrogen gas generates the complex fac-[Re(dien)(PPh(3))(PF(3))(dien)(H(2))](+) (fac-14). T(1) measurements indicate a dihydrogen species with a H-H distance of 1.38 +/- 0.03 Å. The HD analog displays a J(HD) of 6.7 Hz, corresponding to a H-H distance of 1.31 +/- 0.03 Å, a value in good agreement with that determined from T(1) data and among the largest ever measured for an elongated dihydrogen system.

Journal Article↗
PubMedDate not supplied

Syntheses and structures of rhenium(IV) and rhenium(V) complexes with ethanedithiolato ligands.

A novel dimeric rhenium(IV) complex, [Re2(SCH2CH2S)4], and a monomeric methyloxorhenium(V) complex, [CH3ReO(SCH2CH2S)PPh3], were synthesized from methyloxorhenium(V) complexes and characterized crystallographically. The structure of [Re2(SCH2CH2S)4], the formation reaction of which showed surprising demethylation conceivably through the homolytic cleaveage of the rhenium-carbon bond, features distorted trigonal prismatic coordination of sulfurs around the metal center and a rhenium-rhenium triple bond. A revised structure, [Tc2(SCH2CH2S)4], is proposed for a related technetium complex, originally identified as [Tc2(SCH2CH2S)2(SCH=CHS)2] (Tisato et al. Inorg. Chem. 1993, 32, 2042). Additionally, a new compound, CH3Re(O)(SPh)2PPh3, was prepared.

Journal Article↗
PubMed1996

Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use.

Several polyamine ligands L1-L7 were assessed as chelators for rhenium-188 (and by analogy, rhenium-186) for incorporation into the design of radiopharmaceuticals for targeted radiotherapy. Both ease of synthesis of the complexes and their kinetic stability in human serum were examined. Chelation of Re-188 by stannous reduction of perrhenate in the presence of acyclic ligands such as L1 and L2 (L1 = ethylenediamine, L2 = 1,4,8,11-tetraazaundecane) proceeded in acceptable yield (50-90%) under aqueous conditions (pH 11; 20-100 degrees C, 30 min) in a single step. In contrast, synthesis of complexes of the cyclic ligands such as L6 (L6 = 1,4,8,11-tetraazacyclotetradecane, cyclam) in acceptable yield (> 50%) required more involved procedures including use of nonaqueous solvents. The chelates were unambiguously identified as the cationic trans-dioxorhenium(V) tetrakis(amino) complexes, by chromatographic comparison with spectroscopically characterised nonradioactive samples. The complexes of tetradentate ligands L2 and L6 showed no evidence of degradation on incubation for up to 24 h in human serum. The complex of L1 degraded by less than 3% under these conditions. These preliminary studies indicate that the acyclic tetradentate ligands offer an appropriate compromise between biological stability and ease of synthesis, and they have potential as chelators for rhenium in radiopharmaceuticals.

Chelating Agents↗
PubMed2000

[Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].

AIM: Several radiopharmaceuticals were compared previously with regard to the efficiency in pain palliation of bone metastases. Furthermore, first results were reported on the suitability for such kind of therapy of the generator produced radionuclide rhenium-188. METHOD: Influence of Rhenium-188-HEDP (Re-188), Rhenium-186-HEDP (Re-186) and Strontium-89 (Sr-89) on pain symptoms and bone marrow function were obtained in 44 patients (pts). These were 16 pts. with Re-188 (2943 +/- 609 MBq), 13 pts. with Re-186 (1341 +/- 161 MBq) and 15 pts. with Sr-89 (152 +/- 18 MBq) (6 woman with breast cancer and 38 men with prostata cancer). RESULTS: 81 of pts. after Re-188, 77% after Re-186 and 80% after Sr-89 reported relief of pain. The Karnofsky-Index established by pts. increased from 74 +/- 9% to 85 +/- 11% after Re-188, from 70 +/- 11% to 76 +/- 11% after Re-186 and from 62 +/- 10% to 69 +/- 10% after Sr-89. However, the difference between the pre- and the post-therapeutic value is only statistically significant in the case of Re-188 therapy (p = 0.001). A decrease of platelets of 30 +/- 14% after 2.8 +/- 0.7 for pts. treated with Re-188, of 39 +/- 20% after 3.7 +/- 1.0 weeks for pts. treated with Re-186 and of 34 +/- 26% after 4.4 +/- 1.0 weeks for pts. treated with Sr-89 compared to the value before therapy was observed. The difference was not significant between the 3 groups of pts. (p = 0.125 to 0.862). CONCLUSION: All tried radiopharmaceuticals were effective in pain palliation. The various radionuclides had no significant difference in the pain relief or the bone marrow impairment. If only the Karnofsky-Index after Re-188 HEDP seems to be a little more increase.

Bone Neoplasms↗
PubMed2004

Synthesis and reactivity of tris(imido)rhenium complexes containing rhenium-main group element bonds. silicon-carbon bond activations of PhSiH(3) by silyl complexes.

The synthesis and reactivity of a series of complexes of the (DippN=)(3)Re (Dipp = 2,6-(i)Pr(2)C(6)H(3)) fragment are reported. The anionic, Re(V) complex (THF)(2)Li(micro,micro-NDipp)(2)Re(=NDipp) (1), prepared by the reaction of (DippN=)(3)ReCl with (THF)(3)LiSi(SiMe(3))(3) or (t)BuLi (2 equiv) in the presence of THF (4 equiv), served as an important starting material for the synthesis of rhenium-element-bonded complexes. For example, treatment of 1 with ClSiR(3) gave the corresponding silyl complexes (DippN=)(3)ReSiR(3) (SiR(3) = SiMe(3) (2a), SiHPh(2) (2b), SiH(2)Ph (2c)). Complexes 2a-c are thought to exist in equilibrium between the Re(VII) (DippN=)(3)ReSiR(3) and Re(V) (DippN=)(2)ReN(SiR(3))Dipp isomers. Complexes 2a,b reacted with PhSiH(3) to give reaction mixtures that included 2c, Ph(2)SiH(2), SiH(4), and C(6)H(6). The silane and organic products arise from Si-C bond formation and cleavage. Treatment of 2a with CO gave (DippN=)(2)Re[N(SiMe(3))Dipp](CO) (3), which appears to result from trapping of the reactive Re(V) isomer of 2a by CO. Complex 1 reacted with the main group halides MeI, Ph(3)GeCl, Me(3)SnCl, Ph(2)PCl, and PhSeCl to give the corresponding rhenium complexes (DippN=)(3)ReER(n) (ER(n)() = Me (4), GePh(3) (5), SnMe(3) (6), PPh(2) (7), SePh (8)) in high yields. X-ray diffraction data for 5 indicate that the germyl ligand is bonded to rhenium, but positional disorder of the phenyl and Dipp groups prevented refinement of accurate metric parameters.

Journal Article↗
PubMed2006

Rhenium diazenide ternary complexes with dithiocarbamate ligands: towards new rhenium radiopharmaceuticals.

The reaction of the mono-diazenide core, [ReCl2(NNC6H(4)-4-OCH3)(NCCH3)(PPh3)2], with four equivalents of the sodium or potassium salts of dithiocarbamate (dtc) ligands gives neutral complexes of the formula [Re(NNC6H(4)-4-OCH3)(dtc)2(PPh3)]. It is possible to use a wide range of dithiocarbamate ligands (S2CNRR') with a variety of R groups (R=R'=methyl, phenyl or ethyl; R=methyl, R'=phenyl and R=R'=morpholino). Substitution reactions with dtc ligands on the mono-diazenide derived from 2-hydrazinopyridine, [ReCl2(NNC5H4N)(PPh3)2, give the analogous complexes, [Re(NNC6H5N)(dtc)2(PPh3)]. The new complexes have been characterised by a combination of NMR spectroscopy, mass spectrometry and X-ray crystallography. Cyclic voltammetry measurements in dimethyl formamide show that the rhenium diazenido-dtc complexes undergo a quasi-reversible oxidation tentatively assigned to a ReIII/ReIV oxidation. Since the parent complex, [ReCl2(NNC6H(4)-4-R)(NCCH3)(PPh3)2] can be prepared directly from perrhenate and readily derivatised with dtc ligands these complexes have potential relevance to the development of new therapeutic rhenium radiopharmaceuticals.

Crystallography, X-Ray↗
PubMed2005

[X-ray fluorescence spectrometric determination of high rhenium content in rhenium-tungsten alloys used in traveling wave tube].

The matrix effect, spectral overlap and background were investigated for X-ray fluorescence (XRF) spectrometric determination of rhenium content according to the analysis requirement of rhenium-tungsten alloys, a key material used in traveling wave tube. The reason for causing the calibration curve nonlinear was explained theoretically when binary ratio technique of XRF was used. Both theoretical and experimental results show that linear calibration curve can be obtained if the curve is plotted by Re% vs. Re Lalpha X-ray intensity instead of binary ratio technique. The method is rapid and accurate and the results obtained in this work are in good agreement with those of chemical analysis. The method has been successfully applied to product quality control.

Alloys↗
PubMed2004

Removal of dissolved rhenium by sorption onto organic polymers: study of rhenium as an analogue of radioactive technetium.

Technetium (99Tc) is one of the main components of nuclear wastes. Tc characteristics can be predicted by studying rhenium (75Re), one of its chemical analogue, thus avoiding the use of a radioactive element at high concentrations. The objectives of this experimental study was to understand the sorption behavior of Re with natural organic materials in order to define the possible condition of Tc uptake in case where Tc may be transferred into surface or ground waters. As the well-defined organic sorbents we chose chitosan which contains amine -NH2 groups; poly-galacturonic acid (PGA) and poly-styrene sulfonates (PSS) which contain respectively carboxyl -COOH and sulfonate -SO3H groups. Concerning the reaction of Re with PGA or with PSS, no interaction between Re and carboxyl or sulfonate groups was found within the detection limit of this study. Re sorption on chitosan was found to be dependent on ionic strength and pH. We propose that non-specific sorption of perrhenate ion ReO4- via electrostatic interaction takes place at the protonated amine groups NH3+. The polymer-solution interface can be described by the electric diffuse double layer model combined with the Langmuir-Freundlich model. The calculation is in good agreement with our experimental results.

Adsorption↗
PubMed2001

Tricarbonyl[1,1',1"-ethylidynetris(pyrazole-kappaN2)]rhenium(I) bromide and tricarbonyl[methylidynetris(pyrazole-kappaN2)]rhenium(I) iodide ethanol hemisolvate.

The two title compounds, [Re(C(10)H(10)N(6))(CO)(3)]Br and [Re(C(11)H(12)N(6))(CO)(3)]I.0.5C(2)H(6)O, have slightly distorted octahedral geometries about the rhenium centers. The distortions result from the constraints of the eta(3)-coordinated tris(pyrazol-1-yl)methane ligands in each case which reduce the N-Re-N bond angles well below the preferred value of 90 degrees for facially disposed ligands at a six-coordinate metal center.

Journal Article↗
PubMed2000

Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid.

As a generator-produced beta-emitting radionuclide, the importance of 188Re for radionuclide therapy is increasing rapidly. We prepared 188Re-tin colloid and compared its properties with 188Re-sulfur colloid. Labeling efficiencies reached >98% for tin colloid at 2 h and 89-94% for sulfur colloid at 3 h. All the preparations were stable for 72 h in water, serum, and synovial fluid. If labeled at higher temperature, the particle size of tin colloid increased. The residual radioactivity of 188Re-sulfur colloid in disposable polypropylene syringes after injecting mice was high (62.0+/-7.0%) due to its hydrophobic nature, while that of 188Re-tin colloid was low (2.9+/-1.6%). Although both 188Re-tin colloid and 188Re-sulfur colloid might be useful for radionuclide therapy, we conclude that 188Re tin colloid is more advantageous over 188Re sulfur colloid, due to higher labeling efficiency, control of the particle size, and lower residual activity in the injection syringes.

Animals↗
PubMed1992

Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.

The pharmacokinetics of 186Re-HEDP, a radiopharmaceutical for palliative treatment of metastatic bone pain, was investigated in 11 patients (17 studies) who suffered from metastatic breast or prostate cancer. Half-life times of 186Re in three blood fractions (whole blood, plasma and plasma water) were 40.1 +/- 5.0, 41.0 +/- 6.0 and 29.5 +/- 6.4 hr, respectively. Time-dependent increase in plasma-protein binding was observed, probably caused by in vivo decomposition of 186Re-HEDP. Total urinary 186Re excretion was 69% +/- 15%, of which 71% +/- 6% was excreted in the first 24 hr after injection. The BSI (i.e., fraction of the skeleton showing scintigraphic evidence of metastatic disease) closely correlated with the fraction of dose non-renally cleared (r = 0.98). This implies that the amount of radioactivity taken up by the skeleton and hence the bone marrow absorbed dose can be predicted from a diagnostic pre-therapy 99mTc-HDP scintigram. The pharmacokinetic behavior indicates that 186Re-HEDP has suitable properties to justify its application.

Aged↗
PubMed1992

Technetium- and rhenium-labeled progestins: synthesis, receptor binding and in vivo distribution of an 11 beta-substituted progestin labeled with technetium-99 and rhenium-186.

In an effort to develop radiopharmaceuticals useful for the diagnostic imaging of steroid receptor-positive breast tumors, we have radiolabeled an analog of the antiprogestin RU486 (mifepristone), modified to incorporate an N2S2 chelate system in the 11 beta-position, with 99Tc, 99mTc, and 186Re. For the 99Tc-labeled analogs (3), a syn pair and two individual antidiastereomers (linker methylene versus metal-oxo, relative to the N2S2 plane) were isolated. In competitive radiometric binding assays, the syn pair (3syn1,2) had affinity for the progesterone receptor that was 25% that of (promegestone) R5020 (or 161% that of progesterone), and the individual anti-diastereomers had affinities of 47% (3anti1) and 7% (3anti2) that of R5020 (or 303% and 45% that of progesterone). The specific-to-nonspecific binding ratio of the 99mTc (4) and 186Re (5) 11 beta-linked syn systems are 75/25 and 54/46, respectively. In vivo, conjugates 4 and 5 showed progesterone receptor-mediated uptake in rat uterus, but also high uptake in non-target tissues, presumably because of the high lipophilicity of the metal complexes. Modified systems may be useful in vivo as receptor-directed agents for diagnostic imaging or treatment of steroid receptor-positive tumors.

Animals↗
PubMed2002

A new type of tweezer complex involving a rhenium-rhenium multiple bond that enforces an unusual structure in a dipalladium(II) unit.

The substitution of the mu-acetato ligands in cis-Re(2)(mu-O(2)CCH(3))(2)Cl(2)(mu-dppm)(2) (1, dppm = Ph(2)PCH(2)PPh(2)) and trans-Re(2)(mu-O(2)CCH(3))(2)Cl(2)(mu-dppE)(2) (2, dppE = Ph(2)PC(=CH(2))PPh(2)) by [4-Ph(2)PC(6)H(4)CO(2)](-) occurs with retention of stereochemistry to give cis-Re(2)(mu-O(2)CC(6)H(4)-4-PPh(2))(2)Cl(2)(mu-dppm)(2) (3) and trans-Re(2)(mu-O(2)CC(6)H(4)-4-PPh(2))(2)Cl(2)(mu-dppE)(2) (6), respectively. The uncoordinated phosphine groups in complexes 3 and 6 have been used to form mixed-metal assemblies with Au(I) and Pd(II), including the Re(2)Pd(2) complex cis-Re(2)(mu-O(2)CC(6)H(4)-4-PPh(2))(2)Cl(2)(mu-dppm)(2)(Pd(2)Cl(4)) (5), in which the planar [(P)ClPd(mu-Cl)(2)PdCl(P)] unit has the unusual cis structure. The crystal structures of 3 and 5 have been determined.

Journal Article↗